Tagrix 80 mg is an osimertinib film-coated tablet manufactured by Beacon Pharmaceuticals. Beacon identifies the product as containing osimertinib mesylate equivalent to 80 mg of osimertinib.
Osimertinib is an EGFR tyrosine kinase inhibitor used in selected patients with EGFR-mutated non-small cell lung cancer (NSCLC).
Tagrix contains osimertinib, so its medical use is based on the approved indications for osimertinib in the applicable jurisdiction. Current U.S. labeling includes several EGFR-mutated NSCLC settings, including adjuvant therapy, metastatic first-line therapy, selected stage III disease and previously treated T790M-positive metastatic disease.
No. Tagrix and TAGRISSO are different branded products. They contain the same active ingredient, osimertinib, but Tagrix is associated with Beacon Pharmaceuticals and TAGRISSO is an AstraZeneca product.
AstraZeneca developed osimertinib, originally identified during development as AZD9291.
Beacon Pharmaceuticals PLC is identified by its official product information as the manufacturer associated with Tagrix.
Important EGFR alterations include exon 19 deletions, exon 21 L858R and, in the previously treated setting, T790M.
Osimertinib irreversibly inhibits selected mutant forms of EGFR, reducing abnormal signaling that can promote NSCLC cell growth and survival.
The current U.S. labeled dose is 80 mg once daily for the relevant NSCLC indications. The appropriate dose should be determined according to the applicable prescribing information and healthcare professional instructions.
Yes. Current U.S. labeling permits administration of osimertinib with or without food.
Adverse reactions can include diarrhea, rash, dry skin, nail toxicity, stomatitis, fatigue, decreased appetite and other effects. The frequency and severity can vary between patients.
Important risks include interstitial lung disease or pneumonitis, QTc prolongation, cardiomyopathy, keratitis, serious skin reactions, aplastic anemia and embryo-fetal toxicity.
Yes. Interstitial lung disease (ILD) and pneumonitis are recognized serious risks. New or worsening respiratory symptoms should be promptly assessed by a healthcare professional.
Yes. QTc prolongation and cardiomyopathy are recognized risks associated with osimertinib. Appropriate monitoring may be required depending on the patient's clinical circumstances.
Yes. Treatment selection for labeled indications requires appropriate EGFR mutation testing according to the applicable regulatory framework and prescribing information.
Osimertinib can cause embryo-fetal harm. Pregnancy and contraception considerations should be discussed with a healthcare professional before treatment.
Current U.S. labeling advises against breastfeeding during TAGRISSO treatment and for two weeks after the final dose.
Yes. Strong CYP3A4 inducers can reduce osimertinib exposure, and prescribing information provides specific guidance concerning drug interactions. Tell your healthcare professional about all medicines and supplements you use.
Dose reduction or interruption may be necessary for certain adverse reactions. A reduced dose should only be used according to the applicable prescribing information and healthcare professional instructions.
Current TAGRISSO labeling identifies 40 mg and 80 mg tablets. Beacon documentation identifies Tagrix 40 and Tagrix 80 tablets. Product availability should be confirmed against current product documentation.
Check the product name, active ingredient, strength, manufacturer, batch or lot information, expiry date, packaging integrity and applicable authorization information. When in doubt, consult a pharmacist or authorized supply source.